RxDoctor Payments Data

Maria Lauer

Family · Wyndmoor, PANPI 1548782824

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 79 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$801
  • Regeneron Healthcare Solutions, Inc.$332
  • AstraZeneca$159
  • Organon$67
  • Genentech USA, Inc.$49
  • Takeda Pharmaceuticals U.S.A., Inc.$48
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$1,43292%
  • Education$1298%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,562 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,111
Medicare patients
34
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab19$84,082
Breo ElliptaFluticasone/Vilanterol45$25,621
Spiriva RespimatTiotropium Bromide36$21,962
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,672
DuleraMometasone/Formoterol14$8,585
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$5,778
SymbicortBudesonide/Formoterol Fumarate14$5,104
Arnuity ElliptaFluticasone Furoate14$3,325
Wixela InhubFluticasone Propion/Salmeterol18$2,949
Albuterol Sulfate HfaAlbuterol Sulfate77$2,443
Azelastine Hcl65$2,131
Montelukast Sodium127$1,989
Fluticasone Propionate92$1,692
Levocetirizine Dihydrochloride18$548
Ipratropium Bromide12$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$159$5,10414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Wyndmoor

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →